Clinical trial · Observational
Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer
Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments. This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Uterine Cervical Cancer | — | UNRESOLVED | — |
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- neoadjuvant chemotherapy
Primary outcomes (1)
- measure
- The clinical response to neoadjuvant chemotherapy
- timeFrame
- 1 to 3 months
- description
- clinical response（tumor size）
Secondary outcomes (1)
- measure
- The pathological response to neoadjuvant chemotherapy
- timeFrame
- 1 to 3 months
- description
- pathological response（\<3 mm or not）
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Untreated cervical cancer with FIGO stage Ib-IIb * Measurable lesions * Possible to radical hysterectomy * Age: 18 and older * Karnofsky Performance Status≥ 70. * WBC \> 3,000/mm³, Hb \> 9.0g/dl, Platelet \> 100,000 /mm³, SGOT/SGPT \< 60 IU/L, T-Bil \< 1.5 mg/dL, Cr \< 1.2 mg/dL, PaO2 \> 80 torr, normal ECG * Written informed consent Exclusion Criteria: * Previous history of cancer * Patients with previous treatment * Patients without information of clinical risk factors * Patients who have active infection
References
Publications (0)
Data not yet available